Zevra Therapeutics Inc (ZVRA)
9.13
+0.16
(+1.78%)
USD |
NASDAQ |
Nov 21, 16:00
9.145
+0.02
(+0.16%)
Pre-Market: 20:00
Zevra Therapeutics Net Income (Quarterly): -33.22M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -33.22M |
| June 30, 2024 | -19.92M |
| March 31, 2024 | -16.62M |
| December 31, 2023 | -19.89M |
| September 30, 2023 | -10.37M |
| June 30, 2023 | -2.573M |
| March 31, 2023 | -13.22M |
| December 31, 2022 | 5.75M |
| September 30, 2022 | -6.616M |
| June 30, 2022 | -24.04M |
| March 31, 2022 | -1.864M |
| December 31, 2021 | -2.703M |
| September 30, 2021 | -1.759M |
| June 30, 2021 | 6.203M |
| March 31, 2021 | -10.30M |
| December 31, 2020 | -4.856M |
| September 30, 2020 | -3.009M |
| June 30, 2020 | 0.859M |
| March 31, 2020 | -5.754M |
| December 31, 2019 | -6.037M |
| September 30, 2019 | 3.063M |
| June 30, 2019 | -9.257M |
| Date | Value |
|---|---|
| March 31, 2019 | -12.29M |
| December 31, 2018 | -5.183M |
| September 30, 2018 | -15.07M |
| June 30, 2018 | -9.993M |
| March 31, 2018 | -26.22M |
| December 31, 2017 | -10.57M |
| September 30, 2017 | -9.981M |
| June 30, 2017 | -6.517M |
| March 31, 2017 | -16.32M |
| December 31, 2016 | -9.936M |
| September 30, 2016 | -13.41M |
| June 30, 2016 | 9.768M |
| March 31, 2016 | -2.934M |
| December 31, 2015 | -9.203M |
| September 30, 2015 | -9.744M |
| June 30, 2015 | -29.74M |
| March 31, 2015 | -5.974M |
| December 31, 2014 | -11.84M |
| September 30, 2014 | -7.137M |
| June 30, 2014 | -3.572M |
| March 31, 2014 | -1.905M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-33.22M
Minimum
Sep 2024
6.203M
Maximum
Jun 2021
-8.497M
Average
-5.896M
Median
Net Income (Quarterly) Benchmarks
| Ionis Pharmaceuticals Inc | -140.48M |
| Vanda Pharmaceuticals Inc | -5.324M |
| BioCardia Inc | -1.737M |
| Xeris Biopharma Holdings Inc | -15.74M |
| Instil Bio Inc | -23.02M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 3.695M |
| Total Expenses (Quarterly) | 31.00M |
| EPS Diluted (Quarterly) | -0.69 |
| Enterprise Value | 456.85M |
| Gross Profit Margin (Quarterly) | 37.67% |
| Profit Margin (Quarterly) | -899.2% |
| Earnings Yield | -23.11% |
| Normalized Earnings Yield | -22.99 |